Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apyx Medical (APYX) Equity Average (2016 - 2025)

Apyx Medical's Equity Average history spans 15 years, with the latest figure at $10.3 million for Q4 2025.

  • For Q4 2025, Equity Average fell 19.24% year-over-year to $10.3 million; the TTM value through Dec 2025 reached $10.3 million, down 19.24%, while the annual FY2025 figure was $14.4 million, 30.01% down from the prior year.
  • Equity Average reached $10.3 million in Q4 2025 per APYX's latest filing, up from $6.8 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $62.0 million in Q1 2021 to a low of $6.8 million in Q3 2025.
  • Average Equity Average over 5 years is $33.0 million, with a median of $35.8 million recorded in 2023.
  • Peak YoY movement for Equity Average: decreased 12.46% in 2021, then tumbled 62.85% in 2024.
  • A 5-year view of Equity Average shows it stood at $54.3 million in 2021, then dropped by 26.37% to $40.0 million in 2022, then fell by 24.37% to $30.3 million in 2023, then tumbled by 57.8% to $12.8 million in 2024, then decreased by 19.24% to $10.3 million in 2025.
  • Per Business Quant, the three most recent readings for APYX's Equity Average are $10.3 million (Q4 2025), $6.8 million (Q3 2025), and $9.0 million (Q2 2025).